Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan ...
There is a version of the life sciences CEO that the industry tends to celebrate: visionary, decisive, comfortable with risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results